Name | Bersanlimab |
---|
Description | Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1]. |
---|---|
Related Catalog | |
In Vitro | BI-505(1 ng/mL-1000 μg/mL)剂量依赖性地诱导表达 ICAM-1 的 Ramos、Raji 和 Daudi 淋巴瘤细胞的程序性细胞死亡 (PCD)[1]。 |
In Vivo | Bersanlimab(BI-505;20 mg/kg;腹腔注射;每周两次;持续 21 天)显着减少肿瘤生长并延长动物存活期[1]。 Animal Model: SCID mice injected with ARH-77 cells[1] Dosage: 20 mg/kg Administration: i.p.; twice-weekly; for 21 days Result: Significantly reduced tumor growth and prolonged animal survival. |
References |
No Any Chemical & Physical Properties |